Notice Droege Press Release

Immunotec Research Ltd. 300 Joseph Carrier Vaudreuil-Dorion (Québec) Canada J7V 5V5 T : (450) 424-9992 F : (450) 424-9993 www.immunotec.com

Press Release

Renowned German Anti-Aging Researcher Moves to Montreal to Join Immunotec Montreal, March 6, 2006: Charles H. Roberts, President and Chief Executive Officer of Immunotec Research Ltd., is pleased to announce the appointment of Dr. Wulf Droege, one of the world’s leading scientists in aging research, as Senior VicePresident of Research & Development. As head of Immunotec’s R&D department, Dr. Droege will spearhead its research initiatives in the areas of immune system optimization and anti-aging. Dr. Droege previously held the position of professor, Faculty of Biology, at the University of Heidelberg and was Head of the Department of Immunochemistry and redox physiology at Germany’s National Cancer Centre in Heidelberg (Deutsches Krebsforschungszentrum). Dr. Droege has served as the Chairman of Immunotec’s Scientific Advisory Board since 2001. “The whole 65-member team at our head office in Vaudreuil is delighted that Dr. Droege has agreed to settle in the Montreal area, from his native Germany, to take Immunotec’s research activities to new levels of excellence in the fields of aging, cancer cachexia and other disease conditions,” said Roberts. “To recruit such an accomplished scientist is a significant advantage for Canada,” said Roberts. “His presence among us strengthens Montreal’s rapidly expanding biotechnology cluster and its role in world markets. At Immunotec, research is paramount.” After many years of active research into the role of cysteine and glutathione in cell signaling and other biological functions, Dr. Droege was interested to extend this line of research using Immunocal/HMS 90, a natural cysteine delivery system. His

decision to move to Montreal was largely based on his own belief that the full therapeutic potential of Immunocal / HMS 90 has not yet been fully exploited. As part of a clinical development program in cooperation with several clinical partners, Dr. Droege will investigate Immunocal / HMS 90’s impact on: wasting processes in cancer patients, aging and the subsequent impact on quality of life. Dr. Droege has published more than 250 articles in international scientific journals. His research has been focused on the areas of redox regulation and signaling pathways, pathogenesis of HIV infection, the mechanisms of disease-related wasting and aging, and the action of tumor necrosis factor. “We are delighted to have a researcher of Dr. Droege’s experience and accomplishments at the helm of Immunotec’s R&D team, so that we can further strengthen our research base and set new standards for health products for today’s proactive consumer,” said Roberts. Immunotec specializes in the development of new health technologies as a complement to traditional medicine. Combining solid science and business practices, Immunotec delivers a line of dietary supplements, diet aids and related products that contribute to the health, vitality and well-being of people in twenty-two countries around the world. Immunotec Research Limited was co-founded in 1996 when businessmen Roberts and Mr. Dieter Beer, a European industrialist now living in Toronto, joined forces with researcher Dr. Gustavo Bounous, a leading expert in the field of milk science. Immunotec is one of the industry leaders in providing science-based nutritional supplements to the mass market. Its core products Immunocal / HMS 90 are milkbased (whey) protein isolates, patented in Canada and the U.S. with over twenty years of research conducted in University teaching hospitals and medical institutions in Canada and abroad. Immunocal / HMS 90 is the highest quality source for cysteine, and other related ingredients, which are particularly important for the optimal function of the immune system. Immunotec transforms the results of basic research into real products that enhance the health and well-being of the general public. Immunotec’s investment in research sets it apart from other network marketing companies by giving it a competitive edge and assuring that its products are safe and effective. For more information: John H. Molson Vice President, Research & Development [email protected] Work: 450-424-9992 ext. 4450